Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 14/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15233774 | 0.77 | KDM4E (1.00) | LDHAMAPTKDM4EMEN1TP53 | |
| SCHEMBL15269057 | 0.72 | KDM4E (0.76) | LDHAMAPTKDM4EMEN1TP53 | |
| SCHEMBL2085581 | 0.72 | MAPT (0.69) | LDHAMAPTKDM4EMEN1TP53 | |
| SCHEMBL1302687 | 0.71 | NOX4 (1.00) | MAPTMEN1KMT2ATDP1LMNA | |
| SCHEMBL15269516 | 0.69 | MAPT (0.68) | LDHAMAPTKDM4EMEN1TP53 | |
| SCHEMBL15269943 | 0.69 | KDM4E (0.76) | LDHAMAPTKDM4EMEN1TP53 | |
| SCHEMBL4746103 | 0.68 | NOX4 (1.00) | LDHAMAPTKDM4EMEN1TP53 | |
| SCHEMBL13316017 | 0.68 | CDK5 (0.62) | MAPTKDM4EMEN1TP53POLB | |
| SCHEMBL18674670 | 0.67 | AR (0.84) | MAPTKDM4EMEN1TP53ALOX15 | |
| SCHEMBL8798821 | 0.67 | AR (0.61) | MAPTKDM4EMEN1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016845-B2 | BAX activators and uses thereof in cancer therapy | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016845-B2 | BAX activators and uses thereof in cancer therapy | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116615195-A | Combination therapy using BAX activators | 阿尔伯爱因斯坦医学院 | 2023-08-18 | — | — | CN | disclosed |
| EP-4213840-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | Albert Einstein College of Medicine (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11382898-B2 | BAX activators and uses thereof in cancer therapy | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022061174-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382898-B2 | BAX activators and uses thereof in cancer therapy | BAX, BAD, BID | LDHA 586/4885MAPT 4642/4885KDM4E 3699/4885 |
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | BAK1, BCL2L1, BCL2A1 | LDHA 2241/4885MAPT 4406/4885KDM4E 3148/4885 |
| US-12016845-B2 | BAX activators and uses thereof in cancer therapy | BAX, BAD, BID | LDHA 586/4885MAPT 4642/4885KDM4E 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.